Literature DB >> 18275901

Plasmacytoid dendritic cell count on day 28 in HLA-matched related allogeneic peripheral blood stem cell transplant predicts the incidence of acute and chronic GVHD.

Reena Rajasekar1, Vikram Mathews, Kavitha M Lakshmi, Shanmugaapriya Sellathamby, Biju George, Auro Viswabandya, Dolly Daniel, Mammen Chandy, Alok Srivastava.   

Abstract

Dendritic cells (DC) are antigen-presenting cells involved in induction and regulation of immune responses. We investigated the impact of the number of infused and day 28 dendritic cells on the development of acute and chronic GVHD (aGVHD, cGVHD). Monocytoid (MC) and plasmacytoid (PC) dendritic cells were characterized as lin(-)HLA-DR(+)CD11c(+) and lin(-)HLA-DR(+)CD123(+), respectively. Sixty-eight consecutive patients who underwent HLA matched related granuloyte-colony stimulating factor (G-CSF) mobilized allogeneic PBSCT, from February 2005 to May 2006, were included in the analysis. Twenty-three patients developed aGVHD (grade II-IV) and 21 patients had cGVHD. On a univariate analysis the day 28 total DC and the day 28 MC and PC dendritic cells as continuous variables were significantly associated with development of aGVHD and cGVHD. Using an ROC plot analysis a cutoff value for total DC = 10.7/microL, MC = 9.7/microL, and PC = 4.5/microL on day 28 gave the highest likelihood ratios for aGVHD (2.7, 2.14, and 3.29, respectively). On a multivariate analysis, a low day 28 PC (<or=4.5/microL) together with patient age retained their risk for aGVHD (hazard ratio [HR] = 65.1 and 1.0, P-values .000 and .036, respectively), whereas for cGVHD only a low day 28 PC remained significant (HR = 11.8, P = .008). These results suggest that the PC dendritic cell count in the peripheral blood on day 28 is a strong predictor for development of GVHD in recipients of an allogeneic matched related PBSCT.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18275901     DOI: 10.1016/j.bbmt.2007.12.494

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  13 in total

Review 1.  Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.

Authors:  Elizabeth O Stenger; Hēth R Turnquist; Markus Y Mapara; Angus W Thomson
Journal:  Blood       Date:  2012-03-07       Impact factor: 22.113

2.  Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host disease.

Authors:  Mojtaba Akhtari; Cynthia R Giver; Zahir Ali; Christopher R Flowers; Charise L Gleason; Christopher D Hillyer; Jonathan Kaufman; H Jean Khoury; Amelia A Langston; Mary Jo Lechowicz; Sagar Lonial; Heather M Renfroe; John D Roback; Mourad Tighiouart; Louette Vaughn; Edmund K Waller
Journal:  Transfusion       Date:  2010-11       Impact factor: 3.157

Review 3.  GVHD: a continuing barrier to the safety of allogeneic transplantation.

Authors:  Pavan Reddy; Mukta Arora; Martin Guimond; Crystal L Mackall
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

4.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.

Authors:  Sophie Paczesny; Frances T Hakim; Joseph Pidala; Kenneth R Cooke; Julia Lathrop; Linda M Griffith; John Hansen; Madan Jagasia; David Miklos; Steven Pavletic; Robertson Parkman; Estelle Russek-Cohen; Mary E D Flowers; Stephanie Lee; Paul Martin; Georgia Vogelsang; Marc Walton; Kirk R Schultz
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-30       Impact factor: 5.742

Review 5.  Biomarkers in chronic graft-versus-host disease.

Authors:  Jacob Rozmus; Kirk R Schultz
Journal:  Expert Rev Hematol       Date:  2011-06       Impact factor: 2.929

6.  Dendritic Cell Recovery Impacts Outcomes after Umbilical Cord Blood and Sibling Donor Transplantation for Hematologic Malignancies.

Authors:  Waseem Touma; Claudio G Brunstein; Qing Cao; Jeffrey S Miller; Julie Curtsinger; Michael R Verneris; Veronika Bachanova
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-17       Impact factor: 5.742

Review 7.  Biologic markers of chronic GVHD.

Authors:  J Pidala; M Sarwal; S Roedder; S J Lee
Journal:  Bone Marrow Transplant       Date:  2013-07-22       Impact factor: 5.483

Review 8.  Plasmacytoid dendritic cells in allogeneic hematopoietic cell transplantation: benefit or burden?

Authors:  J J Auletta; S M Devine; E K Waller
Journal:  Bone Marrow Transplant       Date:  2015-12-07       Impact factor: 5.483

9.  Absence of STAT1 in donor-derived plasmacytoid dendritic cells results in increased STAT3 and attenuates murine GVHD.

Authors:  Christian M Capitini; Nicole M Nasholm; Christopher D Chien; Shannon M Larabee; Haiying Qin; Young K Song; Peter J Klover; Lothar Hennighausen; Javed Khan; Terry J Fry
Journal:  Blood       Date:  2014-07-25       Impact factor: 22.113

10.  Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa.

Authors:  Matin M Imanguli; William D Swaim; Stacy C League; Ronald E Gress; Steven Z Pavletic; Frances T Hakim
Journal:  Blood       Date:  2009-01-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.